# Filing Detail

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0000950170-24-127845
Filing Date
2024-11-18
Accepted
2024-11-18 12:08:36
Documents
96
Period of Report
2024-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q/A | rgen-20240630.htm iXBRL | 10-Q/A | 3924329
2 | EX-31.1 | rgen-ex31_1.htm | EX-31.1 | 14896
3 | EX-31.2 | rgen-ex31_2.htm | EX-31.2 | 14903
4 | EX-32.1 | rgen-ex32_1.htm | EX-32.1 | 18398
| Complete submission text file | 0000950170-24-127845.txt |  | 19258340

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | rgen-20240630.xsd | EX-101.SCH | 2032574
99 | EXTRACTED XBRL INSTANCE DOCUMENT | rgen-20240630_htm.xml | XML | 5022323

Mailing Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453
Business Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453 7814499560
REPLIGEN CORP (Filer) CIK: 0000730272 (see all company filings)

EIN.: 042729386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 000-14656 | Film No.: 241470440
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)